Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Short Interest Down 68.7% in March

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the recipient of a significant decline in short interest during the month of March. As of March 31st, there was short interest totalling 6,600 shares, a decline of 68.7% from the March 15th total of 21,100 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 58,400 shares, the days-to-cover ratio is presently 0.1 days.

Inhibitor Therapeutics Price Performance

OTCMKTS:INTI remained flat at $0.05 during mid-day trading on Tuesday. Inhibitor Therapeutics has a one year low of $0.04 and a one year high of $0.14. The firm has a market capitalization of $8.67 million, a PE ratio of -5.02 and a beta of -0.61. The firm’s 50 day moving average is $0.06 and its two-hundred day moving average is $0.07.

Inhibitor Therapeutics (OTCMKTS:INTI) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.01) earnings per share for the quarter.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.